• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Genmab A/S

    5/8/25 11:19:36 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMAB alert in real time by email
    6-K 1 gmab_20250508x6k.htm 6-K Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    OF THE SECURITIES EXCHANGE ACT OF 1934
    FOR THE MONTH OF MAY 2025
    COMMISSION FILE NUMBER 001-38976
    Genmab A/S
    (Exact name of Registrant as specified in its charter)
    Carl Jacobsens Vej 30
    2500 Valby
    Denmark
    +45 70 20 27 28
    (Address of principal executive offices)
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F  Form 40-F 
    This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.







    EXHIBIT INDEX
    ExhibitDescription of Exhibit
    99.1
    Interim Report Dated May 8, 2025





    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    GENMAB A/S
    BY:/s/ Anthony Pagano
    Name: Anthony Pagano
    Title: Executive Vice President & Chief Financial Officer

    DATE: May 8, 2025


    Get the next $GMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMAB

    DatePrice TargetRatingAnalyst
    4/1/2025Mkt Perform → Underperform
    Bernstein
    3/11/2025Mkt Perform → Outperform
    William Blair
    2/13/2025$27.00Market Perform → Outperform
    Leerink Partners
    10/8/2024Buy
    Redburn Atlantic
    9/4/2024$31.00Equal-Weight
    Morgan Stanley
    8/20/2024Overweight → Neutral
    JP Morgan
    7/15/2024Sector Perform → Outperform
    RBC Capital Mkts
    2/23/2024$46.00 → $48.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $GMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genmab A/S (Amendment)

      SC 13G/A - GENMAB A/S (0001434265) (Subject)

      2/8/24 10:03:08 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Genmab A/S (Amendment)

      SC 13G/A - GENMAB A/S (0001434265) (Subject)

      2/2/24 2:18:06 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genmab A/S

      SC 13G - GENMAB A/S (0001434265) (Subject)

      2/6/23 2:36:15 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Financials

    Live finance-specific insights

    See more
    • Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

      Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38 Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a

      3/10/25 10:21:00 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

      Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT COPENHAGEN, Denmark; March 10, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising

      3/10/25 10:13:07 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Publishes 2024 Annual Report

      Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email

      2/12/25 11:01:37 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Genmab downgraded by Bernstein

      Bernstein downgraded Genmab from Mkt Perform to Underperform

      4/1/25 9:01:35 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab upgraded by William Blair

      William Blair upgraded Genmab from Mkt Perform to Outperform

      3/11/25 7:35:51 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Genmab from Market Perform to Outperform and set a new price target of $27.00

      2/13/25 7:09:15 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

      Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

      2/22/21 8:00:51 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

      Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trial Full results from the trial will be submitted for presentation at an upcoming medical conference in 2025 Genmab A/S (NASDAQ:GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), following at least one pr

      5/1/25 8:24:00 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

      Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trialFull results from the trial will be submitted for presentation at an upcoming medical conference in 2025 COPENHAGEN, Denmark; May 2, 2024 – Genmab A/S (NASDAQ:GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R

      5/1/25 8:14:12 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

      Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,237 million in the first quarter of 2025. Net trade sales were USD 1,829 million in the U.S. and USD 1,409 million in the rest of the world. Genmab receives royalties on the wo

      4/15/25 6:21:58 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    SEC Filings

    See more
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      5/8/25 11:19:36 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      5/5/25 11:05:13 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      5/1/25 8:21:13 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care